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Abstract
Purpose: The aim of the work was to share the practical experience of preclinical and clinical proton magnetic resonance 
spectroscopy (1HMRS) studies conducted using a 7-Tesla magnetic field strength scanner, taking into account the spec-
ificity of both settings in the context of translational research.
Material and methods: 1HMRS volunteer studies conducted using a Discovery 950 GE 7T scanner, were carried out 
with PRESS sequence, and a VOI measuring 2.0 × 2.0 × 2.0 cm3 placed in the white matter at the parietal occipital 
lobe. Rodent spectra obtained using a 7T Bruker were measured with PRESS, with a VOI 2.0 × 2.0 × 5.5 mm3 placed 
over the hippocampus.
Results: 1HMRS data from humans and rats show that the brain spectra obtained in the same field are characterised 
by a similar neurochemical structure and spectral resolution. Spectra obtained from rats demonstrate the following 
metabolites: NAA, Glu, Gln, Ins, Cho, Cr, PCr, Tau, GABA, Lac, NAAG, and Asp. In turn, spectra from humans 
allowed estimation of the following metabolites: Ala, NAA, Glu, Gln, Ins, Cho, Cr, PCr, Tau, GABA, Lac, NAAG, 
and Asp. Signals from Gln, Glu with chemical shift around 2.4 ppm, from Cr, PCr, and GABA at 3 ppm, and signals 
from Cho and Tau at approximately 3.2 ppm, can be properly separated and estimated both in humans and in rats. 
Conclusions: These results are promising in terms of broadening the knowledge of many neurological diseases by in-
ducing them on animal models and then transferring this knowledge to clinical practice. In spite of this, important 
distinctions in the technical aspects and methodological differences of high-field 1HMRS in both preclinical and 
clinical conditions should be taken into account.
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Introduction
In vivo proton magnetic resonance spectroscopy (1HMRS) 
is a non-invasive diagnostic modality that can measure 
the chemical contents from a selected region of the body. 
Magnetic resonance spectroscopy (MRS) allows noninva-
sive and quantitative assessment of metabolite levels. The 
MRS technique may be used in studies of a wide range of 
diseases across different tissues. Presently,  1HMRS is most 
commonly implemented in the study of the brain; generally, 
in diagnosing brain tumours [1], hypoxia [2], epilepsy [2], 
multiple sclerosis, and infection [3]. Additionally, assess-
ment of psychiatric disorders becomes possible with the 
1HMRS tool, especially depression [4], panic disorders [5], 
and schizophrenia [5]. 1HMRS is also successfully used in 
other anatomical areas, such as breast, liver, and prostate, 
allowing the estimation of tumour aggressiveness and treat-
ment response [2,6]. 
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The strength of the main magnetic field is the key fac-
tor for the spectra quality [7]. Continuous development 
of superconductive magnet technology gives the oppor-
tunity to perform imaging in increasingly high strength 
fields [8]. The first rodent 1HMRS examinations in the 
7-Tesla (T) field date from the 1990s, while the feasibility 
of the method using a 7T scanner applied to the human 
brain was first demonstrated by Tkáč in 2001 [9]. Current-
ly there are about 70 human 7T scanners installed all over 
the world by most leading manufacturers of MRI technol-
ogy [10]. Although high field 7T systems are not allowed 
for use in routine clinical practice, their advantages re-
lated to increasing the main field as well as the accom-
panying technical developments in acquisition relevance, 
field shimming, pulse sequences, or parallel reception and 
transmission support their construction and deployment, 
which practically manifests itself in the growing number 
of clinical trials performed using 7T scanners [11]. 
Typically, human systems working at 7T or higher 
fields are referred to as ultra-high field (UHF) systems [12]. 
This is different from the case of preclinical systems, in 
which 7T has been the standard in recent decades, while 
many new installations are aiming towards higher fields: 
9.4T, 11.7T, and 16T [13]. In the last three decades, many 
MRI/MRS experiments have been conducted on small 
ani mals as an introduction to clinical trials. Rodents are 
the most commonly used group of animals, recommend-
ed for translational studies because there are many genet-
ically modified rodents, being animal models for a num-
ber of diseases [14,15]. Performing clinical and preclinical 
studies in the same field can be very useful from the point of 
view of possible transfer and comparison of the results [8]. 
Development of the technology of human high-field sys-
tems, mostly magnets, makes such studies possible and 
the 7T field is available both for clinical trials and pre-
clinical, animal studies. However, practice of spectroscopy 
studies conducted in clinical and preclinical settings dif-
fers significantly. Patient and animal handling, available 
RF hardware, or problems due to field inhomogeneities 
may serve as examples of their specificity. 
The most important advantages related to an increased 
main field are: increased signal-to-noise ratio (SNR) 
and increased spectral resolution [16]. In consequence, 
high-resolution spectra may be collected in a shorter time 
or from smaller regions, with quality high enough for pre-
cise separation of spectral lines [17,18]. However, there 
are also some issues related to high-field 1HMRS caused 
by inhomogeneity of the magnetic field (B0) and radiofre-
quency field (B1), unwanted signals from outside the vol-
ume of interest (VOI), voxel localisation (Chemical Shift 
Displacement Error – CSDE), and changes in relaxation 
times in high-field systems [19,20].
The motivation of the work was to share the practi-
cal experience of preclinical and clinical 1HMRS studies 
conducted at a field strength of 7T, taking into account 
the specificity of settings and the resulting methodological 
differences in the context of translational research. The 
main technical issues of high-field 1HMRS data acquisi-
tion in both preclinical and clinical studies are discussed.
Material and methods
The data presented here were obtained during 1HMRS 
volunteer studies conducted at Centrum ECO-TECH 
COMPLEX, equipped with a Discovery 950 GE 7T hu-
man system with maximum gradient strength of 50 mT/m 
and slew rate of 200 T/m/s. The configuration of the 
quadrature coil, with two channels for transmission and 
32 channels for receiving (Nova Head 32-channel head 
coil, 2Tx/32Rx), was used to detect the MRS signal. 
1HMRS studies were carried out by SVS technique and PRESS 
sequence (TE/TR = 17 ms/2.500 ms, 256 averages). VOI size 
2.0 × 2.0 × 2.0 cm3 was placed in the white matter at the pa-
rietal occipital lobe. Magnetic field homogeneity was aligned 
using a combination of the standard GE automated localised 
shimming procedure with second-order shim strategies, re-
sulting in water line widths (full width at half maximum, 
FWHM) ranging from 11 Hz to 18 Hz. The signal from 
water was successfully suppressed by variable RF pulses 
with optimised relaxation delay (VAPOR).
Wistar rat studies were performed at the Centre of 
Experimental Medicine, Medical University in Lublin. 
1HMRS spectra were conducted using a 7T MRI scanner 
(70/16 Pharma Scan, Bruker Biospin, GmbH, Germany) 
using a 72 mm transceiver RF coil and a 10 mm or 20 mm 
receive-only surface loop coil. Maximum gradient strength 
and slew rate for this system is 380 mT/m and 330 T/m/s, 
respectively. SVS spectra were measured with PRESS 
sequence (TE/TR = 16 ms/2.500 ms, 1024 averages). 
A 2.0 × 2.0 × 5.5 mm3 VOI was placed over the hippocam-
pus, avoiding contributions from tissue-tissue borders 
and ventricular spaces. Field homogeneity of the VOI was 
achieved with Localised Shim procedure, the FWHM was 
typically in the range of 7 to 13 Hz. VAPOR implementa-
tion was used for water suppression.
Results and discussion 
There are two main factors related to the spectrum 
quality, which increase significantly in high-field condi-
tions. The first is signal-to-noise ratio (SNR), and the sec-
ond is spectral resolution. Both can significantly improve 
the precision of identification and quantification of neu-
rochemical profiles in animal and human studies [21,22].
The main goal of the 1HMRS studies is the accurate 
quantification of the concentration of metabolites in select-
ed regions of the body. The concentration is expressed in 
mmol/l–1 or µmol/g–1 of examined tissue [2]. The strongest 
component of the observed signal always comes from water 
and is approximately 1000 times higher than the strongest 
metabolite signal coming from N-acetyl aspartate (NAA) 
[23]. During spectrum acquisition the water signal is 
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removed. The most popular solutions are Chemical Shift 
Selective Pulses (CHESS), pre-saturating water signal with 
the use of 90° frequency selective pulses followed by crusher 
gradients to diphase the water signal [17] and the varia-
ble pulse power and optimized relaxation delays (VAPOR) 
scheme, which uses seven or eight CHESS pulses with var-
iable flip angle and inter-pulse delays [24]. In our studies 
the VAPOR scheme was used. It is commonly used in MRS 
studies because it enables better water suppression and is 
less sensitive to T1 variation as well as B1 inhomogeneity 
[25] than CHESS, although it lasts longer and increases 
power deposition (SAR) [17]. 
On the other hand, the water signal is needed to make 
adjustment procedures, especially for correction of the 
main field homogeneity (shimming) [26]. Inhomogene-
ity of the main magnetic field may significantly broaden 
spectral lines and thus the benefits resulting from high 
B0 related to the increase of spectral line separation may 
be partially or completely lost [8]. Moreover, a broadened 
water line may be much more difficult to suppress with-
out affecting metabolite lines or spectrum baseline [27]. 
A basic and robust shimming method is based on itera-
tive improvement of water resonance line shape, but [28] 
a good experimental practice is to calculate shim currents 
established on acquired B0 maps, which hold information 
about the spatial distribution of the main field deviation 
in the VOI [29]. 
Animal 1HMRS studies, in which the VOI is generally 
smaller than in humans, show a lower value of water line 
width [25,30]. Preclinical magnets with small bore size 
have a more homogenous magnetic field than human sys-
tems. On the other hand, the ratio of the VOI dimension 
to the size of the whole brain is higher in animal stud-
ies, forcing to care about homogeneity in the VOI. A line 
width about 6-13 Hz was possible in animals at 7 T with 
the use of the B0 mapping technique with an addition-
al iterative automatic shimming for higher-order shims, 
which is the standard shimming protocol offered by most 
vendors. Excellent B0 shimming in human studies at 7T 
results in an optimal line width of about 13-18 Hz with 
the upper limit being the case in anatomically difficult re-
gions, such as the frontal parts of the brain, where suscep-
tibility effects due to the presence of air or bone are sig-
nificant. Figure 1 contains spectra with different FWHM 
values to visualise the effect of B0 shimming on in vivo 
spectral resolution. 
The water signal is also typically used for quantifica-
tion, i.e. relative strengths of water lines are converted 
to concentrations with the use of water signal strength 
and some assumptions necessarily made in relation to 
the water content in the tissue [31]. This is the method 
used by software dedicated to MRS quantification, such 
as LCModelTM software working in the frequency domain 
– the most frequently selected program for spectrum 
analysis in clinical and preclinical settings [32]. Thus, the 
whole MRS acquisition must contain two spectra collect-
ed without and with water line suppression [17]. Figure 2 
shows a spectrum in which the signal from water has 
Figure 1. 1HMRS spectrum from rat hippocampus. Comparison of two spectra with different FWHM values. A) FWHM = 13 Hz, B) FWHM = 6 Hz. PRESS 
sequence: TE 16 ms, TR 2500 ms, 1024 averages, VOI size 2 × 2 × 5.5 mm3. Spectral resolution determined by B0 homogeneity in the VOI (FWHM). 
B0 homogeneity was realised by B0 mapping technique with an additional iterative automatic shimming for higher-order shims. Spectra fitting using 
Top Spin software, 7 T Bruker, animal system
Figure 2. 1HMRS spectrum from rat hippocampus. PRESS sequence: TE 16 ms, 
TR 2500 ms, 32 averages, VOI size 2 × 2 × 5.5 mm3. Attenuation of the first 
RF pulse in VAPOR was selected manually for each animal to reach a satis-
factory level of water suppression (water signal compared to NAA). Spectra 
fitting using Top Spin software, 7T Bruker, animal system
A B
 General technical remarks on 1HMRS translational research in 7T
e193© Pol J Radiol 2019; 84: e190-e197
comparable height to that of the NAA peak, and as a result 
a huge number of chemical compounds can be precisely 
estimated. Metabolite peaks are higher and narrower, the 
baseline of the spectrum is flat, and the residual water sig-
nal is present, which allows for robust estimation of the 
metabolite concentrations [9,32,33]. 
Properly adjusted 1HMRS human and animal spectra 
in high-field systems demonstrate improved frequency 
separation between metabolites, as compared to lower 
fields [12,17], and simplifies the characterisation of mul-
tiplied signals from coupled spin systems [25]. Although 
increasing line separation is counteracted by the increas-
ing width of the spectral lines due to T2 time growth, 
a major improvement in spectral resolution is still signif-
icant, which is related to the fact that separation between 
signals of coupled spins is more accurate[8]. 1HMRS data 
from human and rat brain (Figure 3) clearly show that 
the brain spectra obtained in the same magnetic field are 
characterised by a similar neurochemical structure and 
spectral resolution.
Typically, spectra obtained at 7T allow the correct es-
timation of about 13-18 metabolites in the normal brain 
[34]. 1HMRS spectra obtained from the rat hippocam-
pus demonstrate the following metabolites (Figure 3): 
N-acetyl aspartate (NAA), glutamate (Glu), glutamine 
(Gln), myo-inositol (Ins), choline (Cho), creatine (Cr), 
phosphocreatine (PCr), taurine (Tau), γ-aminobutyric 
acid (GABA), lactate (Lac), N-acetyl aspartyl glutamate 
(NAAG), and aspartate (Asp). In turn, spectra from hu-
man white matter allowed the estimation of the following 
metabolites: alanine (Ala), NAA, Glu, Gln, Ins, Cho, Cr, 
PCr, Tau, GABA, Lac, NAAG, and Asp. The only difference 
is th emissing quantification for the alanine line in the rat 
hippocampus spectrum. As can be seen in Figure 3, the 
signals from Gln, Glu with chemical shift around 2.4 ppm, 
signals from Cr, PCr, and GABA at 3 ppm, and signals 
from Cho, Tau at approximately 3.2 ppm, can be properly 
separated and estimated both in humans and in rats. Also, 
resonance lines from NAA and NAAG were separated. 
Although the background of physical processes taking 
place in observed tissue in animal and human studies with 
respect to 1HMRS is assumed to be the same, there are 
also general differences between clinical and preclinical 
settings related mostly to the signal acquisition and detec-
tion or high magnetic field properties [14]. 
In most human 1HMRS applications, there is no need 
to monitor physiological functions or gating appropriate 
for the study. A distinct procedure is applied in preclinical 
settings where animals are anaesthetised during the whole 
examination to eliminate motion artefacts, and often they 
are additionally immobilised in order to eliminate motion 
completely. Additional care is also necessary throughout 
the study, such as respiratory and ECG monitoring and 
artificial maintenance of the animal temperature in the 
physiological range of 36-37°C to prevent hypothermia. 
In spite of an overall signal increase in high-field 
MRS, there is an important issue of the animal studies 
implied by signal loss related to a small volume of in-
terest (VOI) [35]. The declining quality of the measured 
spectrum can lead to a reduction in the number of me-
tabolites determined in the qualitative analysis. Figure 4 
shows an example of a spectrum with low SNR value, 
in which only nine metabolites (NAA, Glu, Ins, PCho, 
Tau, Gln, Cr, PCr, and GABA) could be assigned, despite 
the preservation of the overall qualitative structure of the 
spectrum as compared with the corresponding spectrum 
with higher SNR. Increase in the SNR can be obtained by 
larger VOI size or additional signal averages (NA) [36]. 
However, attention should be paid because anaesthesia 
of small animals such as mice and rats should not exceed 
Figure 3. 1HMRS spectra obtained at 7T. A) Spectrum from rat hippocampus, PRESS sequence: TE 16 ms, TR 2500 ms, VOI size 2 × 2 × 5.5 mm3. B) Spectra 
from human white matter, PRESS, TE 17 ms, TR 2500 ms, VOI size 2 × 2 × 2 cm3. Chemical shifts are presented relative to TMS (tetramethylsilane), ppm 
value on the horizontal axis in the spectra increases from right (0 ppm) to left (4.2 ppm). The window of this spectra analysis in the LCModel package was 
from 0.2 to 4.6 ppm. The water signal has a chemical shift value at 4.7 ppm; therefore, the water is out of range in this fitting process
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one hour, because changes in the level of metabolites due 
to the effect of the anaesthetic gases (isoflurane/oxygen 
mixture) are possible [37,38]. 
In the example of the rat brain 1HMRS spectrum (Fig-
ure 4B), the above constraints mean that obtaining reason-
ably quantifiable data was possible for 2.0 x 2.0 x 5.5 mm3 
VOI size. In studies with long time of acquisition, the spec-
tra width can increase due to B0 drift. For correct compensa-
tion of the signal loss in animal studies, the number of signal 
averages was 1024. As a consequence, the time of acquisition 
was 40 minutes, and therefore the drift compensation (DC) 
option available with a Bruker 7 T system was used.
Usually, surface coils are used because they have higher 
sensitivity although for the cost of the RF field homoge-
neity. The latter is important for its consequences for the 
measurements of deeper tissue some geometrical restric-
tions arise instead, limiting the number of transmit and re-
ceive channels. Although four-channel receive-only phased 
arrays are in use, setups using single-loop receive-only 
coils are very common – with the diameter approximate to 
the size of the examined part of the subject body, typically 
10-20 mm, for small animal experiments [33].
In theory, the 1HMRS spectrum comes from the signal 
from the selected VOI, and should not contain any con-
tamination from the surrounding tissue [2]. However, in 
practice, subcutaneous lipid signals with a broad chemical 
shift of about 1-2 ppm can significantly deteriorate spectra 
quality (Figure 5). Most vendors provide a solution to this 
problem in the form of an OVS placed in a proper pulse 
sequence [39]. OVS schemes contain hyperbolic secant 
90° RF pulses and crusher gradients, so unwanted coher-
ence rephrasing can be avoided [40]. 
The process of selecting the VOI in high field systems 
has some distinct technical difficulties caused by signif-
icant spatial displacement of volumes for off-resonance 
signals (CSDE) from the prescribed VOI [25]. OVS ap-
plications in preclinical and clinical practice also contrib-
ute to reduction or complete elimination of CSDE [41] 
Currently, the LASER method (localisation by adiabatic 
selective refocusing) replace the STEAM (stimulated echo 
Figure 4. 1HMRS spectrum from rat hippocampus obtained with different SNR (LCModelTM fit): A) 256 signal averages and intrinsic SNR = 22, B) 1024 signal 
averages and intrinsic SNR = 46. PRESS sequence: TE 16 ms, TR 2500 ms, VOI size 2 × 2 × 5.5 mm3. Improvement in SNR value allowed resolution of a larger 
number of well-fitting metabolic profiles (see discussion in the text). 7T Bruker, animal system
Figure 5. 1HMRS spectrum from rat hippocampus. A) spectrum with big signal from lipids, B) spectrum with small signal from lipids. PRESS sequence: 
TE 16 ms, TR 2500 ms, 32 averages, VOI size 2 × 2 × 5.5 mm3. Unwanted signals from lipids can significantly disturb spectra quality. Spectra fitting using 
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acquisition mode) [39] and PRESS (point-resolved spec-
troscopy) [17], basic sequences offered by the vendors for 
high-field 1HMRS studies. In LASER, the adiabatic excita-
tion and refocusing pulses permit minimisation of the un-
wanted effects of the phenomenon that voxels related to 
different metabolites are spatially shifted due to their dif-
ferent resonance frequencies [42]. The subsequent increase 
in power deposition related to the use of long adiabatic 
pulses may be reduced by the use of mixed RF schemes, as 
has been proposed in semi-laser sequence [30]. Although 
localisation techniques with adiabatic pulses are not stand-
ard, they are proposed by most of MRS system vendors as 
available work-in-progress packages.
Human 7T RF technology faces issues of a completely 
different kind, related to RF field distortions originating 
from the fact that the length of the RF wave at 7T is compa-
rable with the human head size [43]. In effect, multichannel 
transmit systems are in use which allow for an adjustment 
of the phase, magnitude, and pulse shape of each RF trans-
mitter, referred to as B1 shimming or RF shimming [44]. 
B1 shimming is not yet widespread in UHF human research 
practice due to the fact that multiple excitation coils and 
specialised RF hardware are required [8]. B1 non-uniformity 
causes fluctuations of the signal intensity and decreases the 
SNR of the MRS data [33]. As a consequence, B1 non-uni-
formity, may disturb the direct interpretation of MRS spec-
tra. 1HMRS animal examinations have fewer technical prob-
lems due to generating insufficient strength of B1 because of 
the small size of the RF coils [33]. 
When moving the 1HMRS experiment from preclini-
cal to clinical settings at 7T, the consideration about SAR 
restriction should always be taken into account. SAR is the 
quantity of energy deposited in imaged tissues by RF puls-
es, and it is proportional to the square of the electric field 
strength [43]. The magnitude of the electric field depends 
both on the B1 amplitude and its change rate, hence it grows 
considerably with B0 strength. The United States Food and 
Drug Administration (FDA) and the International Elec-
trotechnical Commission have established SAR limits for 
the human body [42]. According to these guidelines, the 
SAR value for the head should not exceed 4 W/kg, 8 W/kg 
for the torso, and 12 W/kg for the extremities [43]. How-
ever, it should be remembered that highly heterogeneous 
B1 may produce SAR locally exceeding globally accepted 
values [45]. A slightly different situation is encountered in 
preclinical imaging. In rodents the blood exchange is faster 
due to their considerably smaller size. Moreover, the animal 
body temperature is maintained artificially and controlled 
during scanning. Typically, the animal imaging system has 
no rigid restrictions for SAR limits [14]. 
Interestingly, despite the fact that the 1HMRS method 
has been developed for many years, there are still no guide-
lines regarding the analysis of the results, i.e. the adjustment 
of spectra. There is basically no standard methods of data 
processing and quantification, and they still differ between 
clinical or preclinical laboratories [41]. Spectra quantifica-
tion is generally not straightforward due to the occurrence 
of different assessment approaches [46]. It is possible that 
in the future, thanks to the further development of 1HMRS 
technology and new solutions for the principles of coherent 
quantification for all scientists, this method will find even 
greater application in clinical practice [47].
Conclusions
1HMRS in vivo techniques combined with high mag-
netic field are capable of providing information on a large 
range of neurometabolites with high accuracy. These results 
are promising in terms of broadening the knowledge about 
many neurological diseases by inducing them on animal 
models and then transferring this knowledge to clini-
cal practice. Continuous development of magnetic reso-
nance technology gives an opportunity for transferability 
of experiences from preclinical to clinical settings and for 
translational research in the same field. In spite of this, the 
important distinction in the technical aspects and method-
ological differences of high-field 1HMRS in both preclinical 
and clinical conditions should be taken into account. 
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